gene therapies

News

uniQure sets course to US filing for Huntington gene therapy

Shares in uniQure have rocketed this morning, as it emerges that the FDA will not require it to run a new trial of Huntington's gene therapy AMT-130.

News

Touchdown for Rocket as its first gene therapy gets US okay

Rocket Pharma has won FDA approval for the first gene therapy for LAD-I, a devastating genetic disorder causing severe vulnerability to infections.

News

Boy in a wheelchair looking out to the forest

Regenxbio, Solid report data with Duchenne gene therapies

Regenxbio and Solid Bio say their gene therapies for Duchenne muscular dystrophy show no sign so far of the liver issues seen with Sarepta's Elevidys.

News

New FDA knockback hits uniQure and Huntington patients hard

uniQure looks like it may have to run another trial of its Huntington's disease gene therapy AMT-130, delaying the highly anticipated programme.

News

Black and white image of the side of a baby's face, focused on its ear

Lilly allies with gene-editing firm Seamless on hearing loss

Gene-editing firm Seamless Therapeutics has attracted its first major pharma partner, Eli Lilly, with a $1.12bn alliance focused on hearing loss.

News

A woman hides her face behind her hands, revealing her right eye

Ocugen shares fall, despite positive eye disorder trial

A trial of Ocugen's gene therapy for sight-robbing disease geographic atrophy (GA) showed efficacy – but still sparked a selloff in its shares.

uniQure sets course to US filing for Huntington gene therapy

Touchdown for Rocket as its first gene therapy gets US okay

Regenxbio, Solid report data with Duchenne gene therapies

New FDA knockback hits uniQure and Huntington patients hard

Lilly allies with gene-editing firm Seamless on hearing loss

Ocugen shares fall, despite positive eye disorder trial

ASCO 2026: Can a blood test spot cancer early? with Dr Peter...

Discover a new era of healthcare panel engagement: Grounded ...

gene therapies

Editor's Picks